HC Wainwright Forecasts Biomea Fusion Q1 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Biomea Fusion in a report issued on Wednesday, March 25th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.12) per share for the quarter. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.78) EPS.

BMEA has been the topic of a number of other reports. Citigroup raised their target price on Biomea Fusion from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Friday. Rodman & Renshaw started coverage on Biomea Fusion in a report on Tuesday, January 13th. They set a “buy” rating and a $8.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Biomea Fusion in a research report on Wednesday, January 21st. Wall Street Zen raised Biomea Fusion from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Biomea Fusion in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.75.

Biomea Fusion Price Performance

Shares of Biomea Fusion stock opened at $1.32 on Friday. Biomea Fusion has a 1-year low of $0.87 and a 1-year high of $3.08. The company’s fifty day simple moving average is $1.29 and its 200-day simple moving average is $1.42. The stock has a market capitalization of $95.44 million, a PE ratio of -1.01 and a beta of -0.20.

Institutional Investors Weigh In On Biomea Fusion

A number of institutional investors have recently added to or reduced their stakes in BMEA. Scientech Research LLC purchased a new position in shares of Biomea Fusion in the third quarter worth $25,000. Engineers Gate Manager LP purchased a new position in Biomea Fusion during the second quarter valued at $26,000. Vanguard Personalized Indexing Management LLC bought a new stake in Biomea Fusion in the 3rd quarter valued at $32,000. Millennium Management LLC increased its holdings in Biomea Fusion by 156.7% in the 4th quarter. Millennium Management LLC now owns 25,677 shares of the company’s stock valued at $32,000 after acquiring an additional 15,675 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Biomea Fusion in the 3rd quarter worth $39,000. 96.72% of the stock is owned by hedge funds and other institutional investors.

Biomea Fusion News Summary

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Citigroup raised its price target on BMEA from $6.00 to $7.00 and reiterated a “buy” rating — the new target implies substantial upside versus the current share level. Read More.
• Positive Sentiment: HC Wainwright published a set of updated EPS forecasts (Q1–Q4 2026 and FY2026–FY2028) and materially lifted its multi-year loss estimates (FY2026 from ($1.37) to ($0.57); FY2027 to ($0.64); FY2028 to ($0.78)), signaling the firm expects smaller losses and improving financials over time. The report also lists per-quarter EPS expectations for 2026. Read More.
• Positive Sentiment: D. Boral Capital initiated/maintained a buy rating on Biomea Fusion, adding another independent positive analyst voice. Read More.
• Positive Sentiment: Recent coverage highlights continued strong analyst sentiment driven by encouraging diabetes trial results, supporting the investment case for BMEA’s pipeline upside. Read More.
• Neutral Sentiment: Despite the positive analyst action and trial commentary, the stock is trading lower today — likely a short-term reaction (profit-taking, low liquidity, or risk-off flows common in small-cap biotech) rather than a reversal of analyst views. Monitor trading volume and upcoming clinical or corporate catalysts for signs of follow-through.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.